Articles

Find an Article

Filter articles

Applied Filters

Showing 221 to 230 of 277 results

Ebola IP rights 
in focus

US03-11-2014

The current outbreak of Ebola has devastated communities in West Africa. It has also thrown a light on the complex web of IP rights surrounding the possible treatments for this serious and usually fatal virus, as LSIPR discovered.

HGS: where are we now with SPCs?

EU29-10-2014Ashley Roughton

Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS.

Challenges to the patenting of “essentially biological processes” in India

India29-10-2014Swarup Kumar and Shivaarti Bajaj

A recent decision from the IPAB on the patent eligibility of biological processes could change the biotech playing field in India, say Swarup Kumar and Shivaarti Bajaj.

An alliance for science

US30-09-2014

The Bay Area of California has one 
of the greatest concentrations of life 
sciences companies in the world, 
but its biotech community is being 
threatened by the seemingly 
unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler, 
vice chair, of the new North Bay 
Life Science Alliance to find out 
how it plans to strengthen the network in the area.

US bio/pharma patents under attack

US29-09-2014Arlene Chow and Peter Noh

Increasing numbers of patent challengers are finding the USPTO’s post-grant procedures to be attractive alternatives to district court litigation, write Arlene Chow and Peter Noh.

Mapping the IP Landscape

UK, US04-09-2014Quentin Tannock and Anna Duch

For those who can draw an informative patent map and work out a good navigational route through the complexities, there is an opportunity to gain significant competitive advantages through making the right partnerships, argue Quentin Tannock and Anna Duch.

Patenting stem cells: filing date is the key

EU07-07-2014Joachim Wachenfeld

The EPO generally accepts applications relating to human embryonic stem cells with an effective date after 2008 but discussions about eligibility continue, says Joachim Wachenfeld.

Digital health: rise of the machines

EU, US20-06-2014

Digital health, which brings together digital and genetic data to improve healthcare, will play a vital role in personalised medicine. But there will be significant challenges when it comes to protecting this innovative new area. LSIPR looks at its uses and the potential challenges.

Myriad woes for US innovators

EU, US20-06-2014Bethan Hopewell and Jennifer Antcliff

The USPTO’s new guidance for examiners extends the decision in Myriad beyond isolated nucleic acids to all claims concerning ‘judicial exceptions’. Bethan Hopewell and Jennifer Antcliff report.

The post-Medeva SPC saga: what about biologicals?

EU20-06-2014Jaap Mannaerts

For those involved in the development of biological drugs, the prospects of getting what would seem to be a ‘fair reward’ may not have improved much, says Jaap Mannaerts.

Showing 221 to 230 of 277 results

LSIPR